To illustrate whether the elevated PRKDC protein expression impacts the response of melanomas to chemotherapy, we surveyed the sensitivities of twelve FDA-approved cancer drugs that functioned in blocking DNA synthesis, including 5-FU, Temozolomide (TMZ), Etoposide, Voxlaisib, cisplatin, Oxaliplatin, etc. using published cell line perturbation data from GDSC (https://www.cancerrxgene.org/). This evidence concerns the gene PRKDC and cancer.